Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Open-Label Study to Evaluate Tralokinumab in Atopic Dermatitis Subjects Who Experienced Inadequate Response on Dupilumab

NCT06773455 is registered in ClinicalTrials.gov with Psoriasis Treatment Center of Central New Jersey as lead sponsor.

NCT NCT06773455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06773455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Open-Label Study to Evaluate Tralokinumab in Atopic Dermatitis Subjects Who Experienced Inadequate Response on Dupilumab
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Phase
Phase 4
Overall status
Terminated
Start date
September 11, 2023
Completion date
January 13, 2026
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis